Unexpected Systolic Murmur in an Extremely Low Birth Weight Infant Undergoing Insulin Therapy

Guglielmo Salvatori 1 *, Giulia Brindisi 2 *, Mario Colantonio 3 and Anna Maria Zicari 2

1 Neonatal Intensive Care Unit and Human Milk Bank, Department of Neonatology, Bambino Gesù Children’s Hospital, IRCSS, Rome, Italy
2 Pediatrics Department, Umberto I Hospital, Sapienza University, Rome Italy.
3 Departmentt of Neonatology, S.Camillo Forlanini Hospital, Rome Italy
* Contributed equally
* Correspondence: Giulia Brindisi (giulia.brindisi@gmail.com)

Abstract

Background Hypertrophic cardiomyopathy (HCM) in newborns is a rare and pathological condition with heterogeneous etiologies. Among all the different causes of HCM, hyperinsulinism is not generally reported but the relationship between hyperinsulinism and cardiac hypertrophy (CH) is known.

Case presentation We report the case of cardiac hypertrophy (CH) in an Extremely Low Birth Weight (ELBW) infant who underwent insulin therapy after the onset of a persistent hyperglycemia due to parenteral nutrition (PN); the finding supports the hypothesis of a newborn’s iatrogenic hyperinsulinemia in cardiac involvement. Despite the effects of hyperglycemia on myocardial cells are well known and infants of diabetic mother may develop cardiac malformations, the consequences of an early administration of insulin in preterm infants have never been fully clarified and are often underestimated. The present case underlines the importance of a close cardiological follow-up in infants undergoing insulin infusion for an alteration in the glucose metabolism PN-related, that is a common finding in preterm infants.

Conclusion: This case report, also considering the scientific literature, reiterates the importance of taking into account hyperinsulinism in the differential diagnosis of cardiac hypertrophy.

Keywords Hyperinsulinemia; Hypertrophic cardiomyopathy; Hyperglycemia; Parenteral Nutrition (PN), Extremely Low Birth Weight (ELBW).

Introduction

Hypertrophic cardiomyopathy (HCM) in newborns is a rare and pathological condition in which histological disruption of the myocardial structures creates a thickening of the heart muscle. HCM etiology is extremely heterogeneous, including malformation syndromes, inborn errors of metabolism, neuromuscular disorders even if most cases are due to mutations in cardiac sarcomere protein genes.

Among all the different etiologies of HCM, hyperinsulinism is not generally reported but the relationship between hyperinsulinism and cardiac hypertrophy (CH) is known. In fact hyperinsulinism is mostly linked to CH rather than HCM, which requires histological and functional disaggregation’s criteria. The real cause of CH is particularly important to understand, especially for its implications in clinical practice and for the prognostic and/or therapeutic consequences.
CH is defined by echocardiographic diastolic septal thickness or diastolic left ventricular wall thickness equal to ≥ 2 standard deviations above the mean (Z-score ≥ 1.96; corrected for age, sex, and body size). \(^{3,4,5}\)

In newborns and infants, the etiology of hyperinsulinism can be linked to many different causes: congenital hyperinsulinism (transient and persistent), maternal diabetes, insulin resistance syndromes, hyperinsulinism syndrome-related (such as Becwith-Wiedemann, Costello, Noonan and Leopard syndrome) and hyperinsulinism drug-related (excessive infusion of insulin).\(^1\)

Considering only a few causes of hyperinsulinism among all those listed above, in neonates with **congenital hyperinsulinism**, fetal hyperinsulinemia increases the storage of glucose and lipids with a consequent hyperplasia and hypertrophy of myocardial cells. This is generally a transient phenomenon, secondary to stressfull condition, as the septal thickness progressively decreases to normality within the first months of life, generally without any complications, although in some cases beta-blockers are required.\(^6\)

The persistent congenital hyperinsulinism, instead is due to a focal or diffuse overproduction of insulin originated by the pancreas in relation to various genetic disorders.\(^6\)

Also in **maternal diabetes**, hyperglycemia can produce fetal hyperinsulinemia that can persist till the neonatal period. Hyperglycemia is a known teratogen factor\(^7,8\) and might result in a variety of cardiac defects in newborns.\(^9,10,11,12\)

Even though, epidemiologic and prospective studies have shown that glycosylated hemoglobin A1c level, in the 6 months before conception and during the first trimester of pregnancy, correlates with the increased incidence of major malformations such as neural tube, cardiac defects and spontaneous abortions, the specific effects of hyperglycemia are still unclear.\(^13,14\)

However gestational diabetes acts with a teratogen effect on the embryo, already from the first weeks of gestation, resulting in primary defects of cardiogenesis, related with to the deregulation of expression of genes coding for cardiac development. In the second trimester of gestational age, maternal hyperglycemia and the relative fetal hyperinsulinemia may exclusively cause asymmetric hypertrophic cardiomyopathy, with a thickening of the interventricular septum and lower posterior ventricular wall, which is usually associated with a biventricular dilatation and mitral regurgitation in mesosystolic phase.\(^15\) In infants of diabetic mothers the incidence of congenital cardiac disease is about 3.6%, while this is 0.8% in the general population.\(^16\)

In particular among the 30% of infants without congenital cardiac diseases born from diabetic mothers, the echocardiographic exam shows an interventricular septum and ventricular walls hypertrophy with a ratio from interventricular septal/ left posterior ventricle wall higher than 1,3.\(^17\)

There are also cases of hyperinsulinemia secondary to an **excessive infusion of insulin**, as in the case report presented. A multicenter case-control study, conducted by Bearsall et al., showed that insulin infusion administered to hyperglycemic VLBW infants in the first weeks of life resulted in a significant gain of glucose and total energy intake but with an increased risk of hypoglycemia without providing a significant reduction of mortality and morbidity.\(^18\)

Insulin has the role of an anabolic hormone and acts as a cardiac growth factor, promoting cardiac hypertrophy thanks to the interaction with its receptors on heart muscle cells. So CH related to a hyperinsulineinic condition is characterized by an exuberant growth of single myocardiocytes due to the anabolic insulin effecting the heart as a whole..\(^1\)

Moreover, many authors reported that in the majority of cases, cardiac hypertrophy due to a hyperinsulineinic condition is asymptomatic and also reversible after the normalization of insulin levels.\(^19,20,21,22\)

For the differential diagnosis of hyperinsulinism in newborns see Table n1 below.

**Tab n1. Differential diagnosis of hyperinsulinism in newborns**
| Disease                              | Hyperinsulinism type | Hyperinsulinism trigger cause/etiology |
|-------------------------------------|----------------------|---------------------------------------|
| Transient Congenital hyperinsulinism | Transient            | Maternal Stress                       |
| Persistent Congenital hyperinsulinism | Persistent          | Genetic disorders that cause a focal or diffuse overproduction of insulin in the pancreas. |
| Maternal Diabetes                   | Transient            | Maternal Diabetes                     |
| Hyperinsulinism syndrome-related (such as Becwith-Wiedemann, Costello, Noonan and Leopard syndrome) | Persistent          | Syndromes and genetic disorders       |
| Hyperinsulinism drug-related        | Transient            | Excessive infusion of insulin         |

**Case presentation**

We describe the case of a ELBW infant (25+1 weeks of gestational age, birth weight 880 grams, length 33 cm, cranial circumference 24 cm), born from a caesarean section due to a cervical insufficiency. The mother was a multiparous 27-year-old girl who had shown a shortening of the uterine cervix in the last month of pregnancy and started taking vasosoprexine isoxsuprine hydrochloride to reduce uterine contractions and the possible risk of a premature birth. An intravenous glucocorticoid bolo was administered only few hours before the delivery. The APGAR score was six, one minute after birth and after five minute the newborn underwent orotracheal intubation, surfactant administration and was mechanically ventilated for the following 96 hours. After extubation he was supported with nasal continuous positive air pressure (n-CPAP) and oxygen to maintain oxygen saturation between 90 and 95%. Moreover, the infant developed jaundice and underwent phototherapy until the fourth day of life.

After the first day of life, ibuprofen was started (10 mg/Kg, 4 mg/Kg, 4 Kg/mg to 24 hours apart), due to the presence of a patent ductus arteriosus and eritroprotein (250 units 3 times /week) for the subsequent anemia. No alterations of procalcitonin (PCT) and C-reactive protein (CRP) were detected in order to exclude diagnosis of sepsis. Moreover during hospitalization the child was not undergoing any steroid therapy. The evidence of feeding intolerance (gastric residuals, abdominal distension) required the start of full parenteral nutrition (FPT), but, after 3 days, a persistent hyperglycemia arose (217 mg%).

In order to control blood glucose and gain weight, a continuous insulin infusion was administered for ten days. The infusion rate was adjusted (from 0,1 UI/Kg to 0,01 UI/Kg) to obtain the stabilization of blood glucose levels that was reached after only six days from the beginning of insulin treatment. However, on the 15th day of life, a systolic ejection murmur in mesocardium (2/6) was detected, and the infant developed an episode of desaturation during n-CPAP, requiring an echocardiographic exam and a doxapram hydrochloride infusion was started (0,5 mg/kg/h). Cardiac ultrasonography showed hypertrophic cardiomyopathy with severe thickness of the septum and free wall left ventricular (telediastolic diameter 4,7 mm), reduction of ventricular...
cavity and velocity in ventricular outflow, right trabecular hypertrophy and mild mitral valve insufficiency. On the 17th day of life, electrocardiogram (ECG) showed an elevated ST segment, particularly in the left precordial leads. Subsequently insulin infusion was suspended. The echocardiographic ultrasound exam, after 10 days from insulin suspension, showed a progressive reduction of free left wall septum and of trabecular hypertrophy. After 40 days of life, the ECG was repeated showing a normal tracing and the ecocardiographic ultrasound revealed a further improvement in cardiac hypertrophy. At the time of discharge the baby did not present retinopathy of prematurity (ROP), hypertension, renal failure, but outcomes of bronchodyplasia. At the age of 36 months was in good clinical condition.

Conclusion
The goal of nutrition for preterm infants should be to achieve a postnatal growth rate approximately equal to the rate of a normal fetus with the same gestational age. Unfortunately, most preterm infants, especially ELBW, are not fed sufficient amounts of nutrients to reach normal fetal growth rates. The resulting extrauterine growth retardation is a significant problem that could result in short stature, organ growth failure, neuronal deficits with behavioral problems and low cognitive outcomes. This is the reason why it’s very important to start adequate parental nutrition (PN) to avoid the possible serious consequences of inadequate nutrition for the needs of preterm infants. In the first weeks of life, ELBW infants might present hyperglycemia in the range of 40-80 % of cases. Hyperglycemia among ELBW infants increases the risk of early death, intraventricular hemorrhage and extends the length of hospitalization, which suggests that prevention and treatment of hyperglycemia may improve the outcomes for these infants. Potential causes of hyperglycemia include sepsis, NEC, surgical treatments, infusion of vasoactive drugs and steroids, insulin resistance and/or relative insulin deficiency and high glucose intake, as in the case report described above. The standard approach to the management of hyperglycemia in infants involves the use of glucose restriction and/or continuous insulin infusion to achieve a normal level of glycemia and improve the nutritional uptake. This treatment can prevent osmotic diuresis, dehydration and electrolyte imbalance. In fact, the hyperosmolar state has been associated with an increased risk of intraventricular hemorrhage. However insulin infusion is not free from serious complications, including hypoglycemia that remains an important and risky possible consequence. To the best of our knowledge, the case reported, is the first case described in the literature of an ELBW newborn who shows a transient hyperinsulinemia after birth, due to a iatrogenic intervention, that might be responsible for cardiac complications, as documented by the close temporal relationship between the CH and the beginning, and then the suspension of insulin therapy. Other cases described in literature, refer mainly to CH in presence of congenital hyperinsulinism or maternal diabetes. In this perspective, in the same way as many authors described cases of CH associated with gestational diabetes or congenital hyperinsulinism, the present case highlights the importance of a strict cardiologic follow-up in ELBW infants undergoing PN and subsequently insulin infusion. In fact, the effect of insulin on myocardial cells is well known, even if most of the studies have been performed on rats. Kruger M. et al. explained the association between cardiac hypertrophy and hyperinsulinism in diabetic rats, showing that high fetal insulin, decreases the expression of the N2B titin protein isoform in cardiac cells.
The protein titin is the main mechanism for adjusting passive myocardial stiffness in perinatal heart development and also in chronic heart disease. Insulin controls the cardiac titin-isoform pattern by activating the phosphoinositol-3-kinase pathway.34 Therefore, insulin signaling, regulates both titin-isoform composition and titin phosphorylation, in embryonic cardiomyocytes and could contribute to an altered diastolic function in diabetic cardiomyopathy.34

Other authors suggested that chronic hyperinsulinemia in rats might increase body weight, tibia length, heart weight and left ventricular mass thanks to the anabolic function of this hormone.35 In other studies always conducted on animals, overfeeding is associated with left ventricular hypertrophy36 because it increases the basal level of plasma insulin, leptin and the insulin/glucose ratio.37

On the other hand, in humans in particular, in obese patients with type-2 diabetes mellitus, the hyperinsulinemia in response to hyperglycemia, increases lipids content in myocardial cells.38 In addition, a recent review conducted by Paauw N.D. et al., emphasizes the role of insulin as a cardiac growth factor in hyperinsulinemic infants with CH.1 In fact, the heart is an important target for the anabolic effect of insulin that interacts with its receptors on cardiomyocytes, thus promoting cardiac hypertrophy.39,40 Moreover CH is found in many different hyperinsulinemic diseases, supporting the fact that CH develops regardless of the underlying cause of the high insulin levels.1 In this perspective, we speculate that the pathophysiology underlying cardiac hypertrophy in the infant described might be similar to the one assessed in hypertrophic cardiomyopathy of diabetic mothers’ infants or in congenital hyperinsulinism.41,42,33,22

In conclusion, hyperinsulinism is linked to CH in many different hyperinsulinemic diseases and should be listed in the differential diagnosis of myocardial hypertrophy. The interaction between insulin and its cardiac receptors can produce intracellular growth signals like a growth factor. So, the relationship between hyperinsulinemia and CH needs to be thought to provide the correct clinical practice and the best therapeutic strategies. This is the first case described in the literature of an ELBW, in which a transient cardiac isolated condition, not associated with other pathologies, is due to an iatrogenic hyperinsulemia, and underlines the importance of a close follow-up in infants under insulin treatment, consequent to an altered glucose metabolism during PN. However, the real and causal connection between insulin and CH in hyperinsulinemic conditions still needs to be clarified; in addition, other factors should be better evaluated since CH is not always found in all newborns with high insulin levels. So, further studies are warranted to better define the potential consequences of the prolonged use of insulin therapy, and to clarify the cost-benefit relationship of this therapy in ELBW infants undergoing PN, for a period of their life.

**Consent** Written informed consent was obtained for the publication of this case report.

**List of abbreviations:** Nasal continuous positive air pressure (n-CPAP); Parenteral Nutrition (PN); Extremely Low Birth Weight (ELBW); Very Low Birth Weight (VLBW);; Electrocardiogram (ECG); Retinopathy of prematurity (ROP).

**Authors’ contribution** GS and MC were involved in the patient’s evaluation and clinical care. GS was involved in the conceptualization of the report, literature review, and manuscript preparation; GB was involved in supporting the writing of the original draft and in the review and editing fase.
A.M.Z was involved in the final revision of the manuscript and in supervision. All authors have read and approved the final manuscript.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

Acknowledgments: Not applicable

REFERENCES
1) Paauw ND, Stegeman R, de Vroede MAMJ, Termote JUM, Freund MW, Breur JMPJ. Neonatal cardiac hypertrophy: the role of hyperinsulinism—a review of literature. Eur J Pediatr. 2020 Jan;179(1):39-50.
2) Moak JP, Kaski JP (2012) Hypertrophic cardiomyopathy in children. Heart 98:1044–1054.
3) American College of Cardiology Foundation/American Heart Association Task Force on Practice; American Association for Thoracic Surgery; American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Failure Society of America; Heart Rhythm Society; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons, Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg. 2011 Dec;142(6):e153–203.
4) Chubb H, Simpson JM (2012) The use of Z-scores in paediatric cardiology. Ann Pediatr Cardiol 5:179–184.
5) Daubeney PE, Blackstone EH, Weintraub RG et al (1999) Relationship of the dimension of cardiac structures to body size: an echocardiographic study in normal infants and children. Cardiol Young 9:402–410
6) Huang, TingTing, et al. "Hypertrophic cardiomyopathy in neonates with congenital hyperinsulinism." Archives of Disease in Childhood-Fetal and Neonatal Edition 98.4 (2013): F351-F354.
7) Reece EA, Homko CJ, Why do diabetic women deliver malformed infants? Clinical obstetrics and gynecology 2000, 43(1):32-45.
8) Nasri HZ, Houde Ng K, Westgate MN, Hunt AT, Holmes LB., Malformations among infants of mothers with insulin-dependent diabetes: Is there a recognizable pattern of abnormalities? Birth Defects Res. 2018 Jan;110(2):108-113.
9) Yang J, Cummings EA, O’Connell C, Jangaard K, Fetal and neonatal outcomes of diabetic pregnancies. Obstetrics and gynecology 2006, 108(3 Pt 1):644-650.
10) Mohsin M, Sadqani S, Younus K, Hoodbhoy Z, Ashiqali S, Atiq M. Evaluation of cardiac function in fetuses of mothers with gestational diabetes. Cardiol Young. 2019 Oct;29(10):1264-1267
11) Temple RC, Aldridge VJ, Murphy HR: Prepregnancy care and pregnancy outcomes in women with type 1 diabetes. Diabetes care 2006, 29(8):1744-1749.
12) Murphy HR, Bell R, Dornhorst A, Forde R, Lewis-Barned N., Pregnancy in Diabetes: challenges and opportunities for improving pregnancy outcomes., Diabet Med. 2018 Mar;35(3):292-299
13) Schaefer UM, Songster G, Xiang A, Berkowitz K, Buchanan TA, Kjos SL: Congenital malformations in offspring of women with hyperglycemia first detected during pregnancy. American journal of obstetrics and gynecology 1997, 177(5):1165-1171.
14) Asoglu MR, Gabbay-Benziv R, Turan OM, Turan S., Exposure of the developing heart to diabetic environment and early cardiac assessment: A review,. Echocardiography. 2018 Feb;35(2):244-257
15) Breithardt, Günter, and Ole-Alexander Breithardt. "Left Bundle Branch Block, an Old–New Entity." Journal of cardiovascular translational research 5.2 (2012): 107-116.
16) Wren C, Birrell G, Hawthorne G., Cardiovascular malformations in infants of diabetic mothers, Heart. 2003 Oct;89(10):1217-20
17) Abu-Sulaiman, R. M., and B. Subaih. "Congenital heart disease in infants of diabetic mothers: echocardiographic study." Pediatric cardiology 25.2 (2004): 137-140.
18) Beardsall K, Vanhaebruck S, Ogilvy-Stuart AL, Vanhole C, Palmer CR, van Weissenbruch M, Midgley P, Thompson M, Thio M, Cornette L et al: Early insulin therapy in very-low-birth-weight infants. The New England journal of medicine 2008, 359(18):1873-1884.
19) Oberhoffer R, Hogel J, Stoz F et al (1997) Cardiac and extracardiac complications in infants of diabetic mothers and their relation to parameters of carbohydrate metabolism. Eur J Pediatr 156:262–265
20) Massin MM, Van Elmbt G, Soyeur D (1999) Reversible hypertrophic cardiomyopathy in congenital hyperinsulinism. Acta Cardiol 54:359–361
21) Jeninga EH, de Vroede M, Hamers N et al (2012) A patient with congenital generalized lipodystrophy due to a novel mutation in BSCL2: indications for secondary mitochondrial dysfunction. JIMD Rep 4:47–54.
22) Huang T, Kelly A, Becker SA et al (2013) Hypertrophic cardio- myopathy in neonates with congenital hyperinsulinism. Arch Dis childhoodFetal neonatal Ed 98:F351–F354.
23) Hay WW, Jr.: Strategies for feeding the preterm infant. Neonatology 2008, 94(4):245-254.
24) Harding JE, Cormack BE, Alexander T, Alsweiler JM, Bloomfield FH. Advances in nutrition of the newborn infant. , Lancet. 2017 Apr 22;389(10079):1660-1668.
25) S.M. Ng, J.E. May, A.J. Emmerson. Continuous insulin infusion in hyperglycaemic extremely-low-birth-weight neonates Biol Neonate, 87 (4) (2005), pp. 269–272.
26) Hays SP, Smith EO, Sunehag AL: Hyperglycemia is a risk factor for early death and morbidity in extremely low birth-weight infants. Pediatrics 2006, 118(5):1811-1818.
27) Stensvold HJ, Strommen K, Lang AM, Abrahamsen TG, Steen EK, Pripp AH, Ronnestad AE.Early Enhanced Parenteral Nutrition, Hyperglycemia, and Death Among Extremely Low-Birth-Weight Infants. JAMA Pediatr. 2015 Nov;169(11):1003-10
28) Thureen PJ. Early aggressive nutrition in the neonate. Neo Rev 1999; 44: e45-e55
29) Aldana-Valenzuela C., Early Aggressive Nutrition in Premature Infants: Is This the Best Approach? J Pediatr Gastroenterol Nutr. 2015 Sep;61(3):269-70.
30) V Kairamkonda, Does continuous insulin infusion improve glycemic control and nutrition in hyperglycaemic very low birth weight infants?, Arch Dis Child 2006;91:74–83.
31) Dawid G, Wegrzynowski J, Kwatike M, Bieczyk-Mokosa A, Petriczko E, Horodnicka-Jozwa A: A fetal dilated and hypertrophic cardiomyopathy associated with maternal gestational diabetes--a case report. Pediatric endocrinology, diabetes, and metabolism 2010, 16(2):123-125.
32) Chaudhari M, Brodlie M, Hasan A: Hypertrophic cardiomyopathy and transposition of great arteries associated with maternal diabetes and presumed gestational diabetes. Acta Paediatr 2008, 97(12):1755-1757
33) Breitweser JA, Meyer RA, Sperling MA et al (1980) Cardiac septal hypertrophy in hyperinsulinemic infants. J Pediatr 96:535–539
34) Kruger M, Babicz K, von Frieling-Salewsky M, Linke WA: Insulin signaling regulates cardiac titin properties in heart development and diabetic cardiomyopathy. Journal of molecular and cellular cardiology 2010, 48(5):910-916.
35) Samuelsson AM, Bollano E, Mobini R, Larsson BM, Omerovic E, Fu M, Waagstein F, Holmang A: Hyperinsulinemia: effect on cardiac mass/function, angiotensin II receptor expression, and insulin signaling pathways. American journal of physiology Heart and circulatory physiology 2006, 291(2):H787-796.
36) Moreira AS, Teixeira Teixeira M, da Silveira Osso F, Pereira RO, de Oliveira Silva-Junior G, Garcia de Souza EP, Mandarim de Lacerda CA, Moura AS: Left ventricular hypertrophy induced by overnutrition early in life. Nutrition, metabolism, and cardiovascular diseases : NMCD 2009, 19(11):805-810.
37) Mandarim-de-Lacerda CA: Stereological tools in biomedical research. Anais da Academia Brasileira de Ciencias 2003, 75(4):469-486.
38) Jankovic D, Winhofer Y, Promintzer-Schifferl M, Wohlschlager-Krenn E, Anderwald CH, Wolf P, Reiter G, Trattnig S, Luger A et al: Effects of insulin therapy on myocardial lipid content and cardiac geometry in patients with type-2 diabetes mellitus. PloS one 2012, 7(12):e50077.
39) Bar RS, Boes M, Dake BL et al (1988) Insulin, insulin-like growth factors, and vascular endothelium. Am J Med 85:59–70
40) Ren J, Samson WK, Sowers JR (1999) Insulin-like growth factor I as a cardiac hormone: physiological and pathophysiological im- plications in heart disease. J Mol Cell Cardiol 31:2049–2061
41) Ullmo S, Vial Y, Di Bernardo S, Roth-Kleiner M, Mivelaz Y, Sekarski N, Ruiz J, Meijboom EJ: Pathologic ventricular hypertrophy in the offspring of diabetic mothers: a retrospective study. European heart journal 2007, 28(11):1319-1325.
42) Topcuoglu S, Karatekin G, Yavuz T, Arman D, Kaya A, Gursoy T, Ovalı F., The relationship between the oxidative stress and the cardiac hypertrophy in infants of diabetic mothers., Diabetes Res Clin Pract. 2015 Jul;109(1):104